Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

DISEASE CHARACTERISTICS: * Diagnosis of Waldenstrom's macroglobulinemia confirmed by IgM gammopathy and bone marrow biopsy * Presence of lymphoplasmacytic cells * CD20+ plasma cell dyscrasia on the majority of malignant cells * Bone marrow involvement of 20-50% by core needle biopsy of at least 1.5 cm in length * Clinical indication for initiation of treatment, including 1 or more of the following characteristics: * Symptoms associated with the disease (e.g., fatigue, asthenia, or painful adenopathy) * Anemia * IgM greater than 3 g/L * Progression as indicated by a rate of IgM rise of more than 0.5 g over 6 months * No myelodysplastic syndromes or profound hypocellularity of the bone marrow PATIENT CHARACTERISTICS: Age * Over 18 Performance status * WHO 0-2 Life expectancy * More than 3 months Hematopoietic * Absolute neutrophil count greater than 1,500/mm\^3 * Total B-lymphocyte count less than 5,000/mm\^3 * Platelet count greater than 100,000/mm\^3 * No hyperviscosity syndrome Hepatic * Bilirubin no greater than 1.5 mg/dL Renal * Not specified Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 1 year after study completion * No uncontrolled CNS disease * No serious nonmalignant disease that would preclude study participation * No other concurrent active malignancy except controlled skin cancer or prostate cancer PRIOR CONCURRENT THERAPY: Biologic therapy * More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF) * More than 4 months since prior rituximab * No prior radioimmunotherapy Chemotherapy * No prior high-dose chemotherapy (unless patient has had prior back-up stem cell collections) * More than 6 weeks since prior chemotherapy Endocrine therapy * More than 4 weeks since prior corticosteroids Radiotherapy * No prior radiotherapy Surgery * Not specified